AbbVie Inc. (NYSE:ABBV) Shares Bought by Community Bank of Raymore

Community Bank of Raymore lifted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 12.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,899 shares of the company's stock after purchasing an additional 1,520 shares during the period. AbbVie comprises 1.9% of Community Bank of Raymore's investment portfolio, making the stock its 18th biggest position. Community Bank of Raymore's holdings in AbbVie were worth $2,470,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Groupama Asset Managment lifted its stake in shares of AbbVie by 40.3% in the third quarter. Groupama Asset Managment now owns 135,749 shares of the company's stock worth $27,000 after buying an additional 38,974 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of AbbVie in the third quarter valued at approximately $28,000. Retirement Wealth Solutions LLC acquired a new position in AbbVie during the fourth quarter worth $35,000. Marquette Asset Management LLC purchased a new stake in AbbVie in the 3rd quarter valued at $39,000. Finally, Mizuho Securities Co. Ltd. raised its holdings in shares of AbbVie by 100.0% during the 3rd quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company's stock worth $39,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Stock Performance

Shares of ABBV stock traded up $0.06 during mid-day trading on Tuesday, hitting $171.62. 3,319,685 shares of the stock were exchanged, compared to its average volume of 5,359,139. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $207.32. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The stock has a market capitalization of $303.28 billion, a price-to-earnings ratio of 59.59, a P/E/G ratio of 1.69 and a beta of 0.58. The stock's fifty day simple moving average is $175.72 and its two-hundred day simple moving average is $184.80.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.92 by $0.08. The firm had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.95 EPS. On average, analysts forecast that AbbVie Inc. will post 10.06 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $1.64 per share. This is an increase from AbbVie's previous quarterly dividend of $1.55. The ex-dividend date is Wednesday, January 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.82%. AbbVie's dividend payout ratio is 227.78%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Truist Financial reduced their target price on shares of AbbVie from $215.00 to $211.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. UBS Group increased their price objective on AbbVie from $195.00 to $200.00 and gave the stock a "neutral" rating in a research report on Thursday, October 31st. Wolfe Research began coverage on AbbVie in a report on Friday, November 15th. They set an "outperform" rating and a $205.00 price target for the company. Sanford C. Bernstein began coverage on shares of AbbVie in a research report on Thursday, October 17th. They issued a "market perform" rating and a $203.00 target price on the stock. Finally, Morgan Stanley reduced their price target on shares of AbbVie from $231.00 to $224.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 12th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $205.50.

Insider Buying and Selling

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.25% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.